Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 17, 2026 | BlueCross BlueShield of Tennessee | Lipectomy and Liposuction for Lymphedema | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Linvoseltamab-gcpt (Lynozyfic) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Light Emitting Diode (LED) Therapy | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Levoleucovorin (Fusilev), Levoleucovorin (Khapzory), Levoleucovorin | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Suspension (Lupron Depot, Leuprolide Acetate Depot)1-Month 3.75mg, 3-Month 11.25 mg) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Mesylate (Camcevi ETM; Camcevi Kit) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate (Eligard, Vabrinty) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate (Fensolvi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate Depot Suspension - [Lupron Depot (1 month) 7.5mg, Lupron Depot (3 month) 22.5mg, Lupron Depot (4-Month) 30 mg, Lupron Depot (6-Month) 45 mg]; Leuprolide Acetate Depot (3-month 22.5 mg): Lutrate Depot (3-month 22.5 mg) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Leuprolide Acetate Depot Suspension (Lupron Depot-Ped) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sargramostim (Leukine) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Lecanemab-irmb (Leqembi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Treatment for Lyme Disease | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | LASIK (laser in situ keratomileusis) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Laser Therapy for Onychomycosis and Active Acne | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Laser Device for Obtaining Blood Sample | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Laser Assisted Uvulopalatoplasty (LAUP) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Laparoscopic, Percutaneous and Transcervical Techniques for the Myolysis of Uterine Fibroids | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Lanreotide (Somatuline Depot; Lanreotide*) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Lanadelumab-flyo (Takhzyro) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Velmanase Alfa-tycv (Lamzede) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Percutaneous Vertebroplasty, Kyphoplasty, and Mechanical Vertebral Augmentation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tisagenlecleucel (Kymriah) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pegloticase (Krystexxa) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Kinesio Taping | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Tebentafusp-tebn (Kimmtrak) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Uveal Melanoma | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pembrolizumab (Keytruda) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Sebelipase Alfa (Kanuma) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Mitomycin Gel(Jelmyto) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ixabepilone (Ixempra) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Pancreas/Pancreas-Kidney/Pancreatic Islet Cell Transplantation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Isatuximab-irfc (Sarclisa) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Irinotecan Liposome Injection (Onivyde) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ipilimumab (Yervoy) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intrastromal Corneal Ring Segments (ICRS) for Vision Correction | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intraoral Devices for the Treatment of Headaches | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intraoperative Radiation Therapy (IORT) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intestinal Transplantation | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intensive Outpatient Pediatric Feeding Program | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Intensity-Modulated Radiotherapy (IMRT) of the Breast and Lung | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Inotersen (Tegsedi) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Trigger Point Injections | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Ingestible pH and Pressure Capsule | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Infliximab Products: Infliximab (Remicade); Infliximab axxq (Avsola), Infliximab dyyb (Inflectra); Infliximab abda (Renflexis); Infliximab-dyyb (Zymfentra), Infliximab | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Inebilizumab-cdon (Uplizna) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | Inclisiran (Leqvio) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | IncobotulinumtoxinA(Xeomin) | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | In Vitro Particle Size Measurement for Screening Hypersensitivity Reactions to Foods and Chemicals | Criteria changed |
| May 17, 2026 | BlueCross BlueShield of Tennessee | DESCRIPTION | Criteria changed |